Nektar Therapeutics (NASDAQ: NKTR) kicked off on Monday, down -11.14% from the previous trading day, before settling in for the closing price of $0.55. Over the past 52 weeks, NKTR has traded in a range of $0.53-$1.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.50% over the last five years. While this was happening, its average annual earnings per share was recorded -8.51%. With a float of $179.37 million, this company’s outstanding shares have now reached $185.78 million.
The firm has a total of 61 workers. Let’s measure their productivity. In terms of profitability, gross margin is 68.82%, operating margin of -92.39%, and the pretax margin is -121.1%.
Nektar Therapeutics (NKTR) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Nektar Therapeutics is 3.62%, while institutional ownership is 69.47%. The most recent insider transaction that took place on Feb 19 ’25, was worth 10,403. In this transaction Chief R&D Officer of this company sold 10,300 shares at a rate of $1.01, taking the stock ownership to the 316,604 shares. Before that another transaction happened on Feb 19 ’25, when Company’s Chief Legal Officer sold 11,040 for $1.01, making the entire transaction worth $11,150. This insider now owns 324,292 shares in total.
Nektar Therapeutics (NKTR) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.18 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -8.51% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -11.68% during the next five years compared to 25.49% growth over the previous five years of trading.
Nektar Therapeutics (NASDAQ: NKTR) Trading Performance Indicators
Take a look at Nektar Therapeutics’s (NKTR) current performance indicators. Last quarter, stock had a quick ratio of 4.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.93.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.58, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.69 in one year’s time.
Technical Analysis of Nektar Therapeutics (NKTR)
Analysing the last 5-days average volume posted by the [Nektar Therapeutics, NKTR], we can find that recorded value of 3.54 million was better than the volume posted last year of 2.2 million. As of the previous 9 days, the stock’s Stochastic %D was 6.12%. Additionally, its Average True Range was 0.08.
During the past 100 days, Nektar Therapeutics’s (NKTR) raw stochastic average was set at 2.56%, which indicates a significant decrease from 5.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.76% in the past 14 days, which was lower than the 83.12% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.8091, while its 200-day Moving Average is $1.0986. Now, the first resistance to watch is $0.5371. This is followed by the second major resistance level at $0.5839. The third major resistance level sits at $0.6194. If the price goes on to break the first support level at $0.4548, it is likely to go to the next support level at $0.4193. Now, if the price goes above the second support level, the third support stands at $0.3725.
Nektar Therapeutics (NASDAQ: NKTR) Key Stats
The company with the Market Capitalisation of 91.27 million has total of 186,104K Shares Outstanding. Its annual sales at the moment are 98,430 K in contrast with the sum of -118,960 K annual income. Company’s last quarter sales were recorded 29,180 K and last quarter income was 7,260 K.
